{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-013066","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2023-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.412576+00:00","generated_at":"2026-06-16T12:04:40.490991+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xencor appoints Nancy Valente as EVP, Chief Development Officer; board reduced to 7","bullets":["Nancy Valente appointed EVP and Chief Development Officer effective May 1, 2023; she resigned from board.","Valente previously SVP at Genentech/Roche; led development of GAZYVA, VENCLEXTA, POLIVY, HEMLIBRA.","Compensation: $540K base salary, 50% bonus target, option grant for 235,778 shares ($3.9M), RSU grant of 39,269 shares ($1.3M).","Allen Yang steps down as executive officer effective May 1 but stays in non-executive role.","Board size reduced from 8 to 7 to eliminate vacant seat left by Valente."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-013066","json":"https://secwatch.observer/filing/0001628280-23-013066.json","markdown":"https://secwatch.observer/filing/0001628280-23-013066.md","text":"https://secwatch.observer/filing/0001628280-23-013066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000162828023013066/0001628280-23-013066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000162828023013066/xncr-20230424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T12:04:40.490991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"32a17146a6","claim":"Nancy Valente resigned as Director at Xencor Inc.","evidence_excerpt":"Dr. Nancy Valente tendered her offer of resignation from the Board of Directors (the \"Board\") of Xencor, Inc. (the \"Company\"), subject to the Board's acceptance of her resignation. Also on April 24, 2023, the Board accepted Dr. Valente's resignation, effective as of May 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326732/000162828023013066/0001628280-23-013066-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"653e4206a4","claim":"Allen Yang changed role as executive officer at Xencor Inc.","evidence_excerpt":"Dr. Allen Yang will step down from his role as an executive officer of the Company. He will continue to be employed by the Company in a non-executive capacity.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326732/000162828023013066/0001628280-23-013066-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"executive officer"}],"fact_type":"executive_change"},{"claim_id":"f6f7312d66","claim":"Nancy Valente was appointed as Executive Vice President and Chief Development Officer at Xencor Inc.","evidence_excerpt":"Dr. Nancy Valente, age 64, was appointed as Executive Vice President and Chief Development Officer of the Company, effective May 1, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326732/000162828023013066/0001628280-23-013066-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and Chief Development Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}